Guidant and Micro expand European agreement:
This article was originally published in Clinica
Guidant is to have exclusive European distribution rights to Micro Therapeutics' Embolyx technology for peripheral vascular emobolisation applications. Guidant gained exclusive distribution rights to Micro's neurovascular products in Europe in November 1997. Under the original deal, Guidant agreed to invest up to $10 million in the San Clemente, California-based company. $7.5 million has been paid to date. The remaining $2.5 million is subject to Micro achieving a milestone by the end of the year.
You may also be interested in...
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
Resilience has raised $800m to develop new technologies to manufacture complex drugs including vaccines, cell therapies and gene therapies.
Results of three-year study conducted at 17 Canadian sites suggest that e-cigarettes use combined with counseling significantly increased abstinence from smoking cigarettes compared to receiving counseling alone.